The global RNA targeted therapeutics market size is expected to be worth USD 1.81 Billion in 2025. It can reach a valuation of USD 15.10 Billion by 2032. The market is anticipated to peak at a CAGR of 35.4% during the forecast period (2025-2032).
The rise in cancer cases and the acceptance of RNA therapies for major diseases can drive the market growth significantly. The large scope for RNA targeted therapeutics and a surge in clinical trials for targeting cardiometabolic disorders can bode well for the market.
However, the high development and commercialization costs for RNA targeted therapeutics can impede the market growth.
Key Market Insights
The RNA targeted therapeutics market is anticipated to expand owing to novel launches in mRNA vaccines, applications in oncology, and incentives for fueling innovation for a large patient pool.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/rna-targeted-therapeutics-market
RNA Targeted Therapeutics Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 1.81 Billion |
|
Estimated Value by 2032 |
USD 15.10 Billion |
|
Growth Rate |
35.4% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The RNA targeted therapeutics market benefited from the COVID-19 pandemic. The development of RNA vaccines for the fight against various strains of COVID-19 vouched for its efficacy and safety. This gave a boost to common types of RNA, namely ASOs, messenger RNA (mRNAs), and small-interfering RNA (siRNAs).
A surge in mergers and acquisitions and investments in RNA therapies bolstered the market growth effectively. In 2021, Pfizer spent more than USD 600 million on the acquisition of Trillium Therapeutics. Furthermore, the use of RNA interference (RNAi) therapeutics for the effective treatment of advanced cancer created growth opportunities for the market.
Market Opportunity: Popularity of mRNA Therapies to Boost Market Demand
The rise of mRNA vaccines due to collaborative efforts between biopharmaceutical companies and startups can drive the market demand significantly. Investments by venture capital firms and government agencies to attain vaccines against newer virus strains and oncological disorders can facilitate the RNA targeted therapeutics market. The Native Antigen Company generated aptamers on February 10, 2025, using Systematic Evolution of Ligands by EXponential enrichment (SELEX) with virus-like particles (VLPs) against the chikungunya virus.
Market Challenge: Pushback against Orphan Drugs Protection in Europe
The future introduction of Joint Clinical Assessment (JCA) in Europe for oncology and advanced therapy medicinal products (ATMPs) starting in 2025 and orphan products starting in 2028 can impact the protection enjoyed by orphan drugs. Orphan drugs, produced on a small budget and targeted for rare diseases, are expected to undergo various policy reforms as they become viable by the masses. The pushback by drug manufacturers against the leniency towards their evaluation and faster approval can lead to fewer approvals. The loss of market exclusivity and data protection can negatively impact the RNA targeted therapeutics market growth globally.
Analyst’s View
Recent Developments
Novartis AG acquired Regulus Therapeutics on June 25, 2025, for USD 1.7 billion. The acquisition can fuel the development of farabursen, a microRNA-17 inhibitor for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :